Antibody-drug conjugates (ADCs): all 1,111 studies that test it

Page 7 of 12. Open to participants first (502), then studies with results posted, then the rest; newest registration first within each.

• Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial CancerCompletedNCT03523572Phase 1Results posted
• Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II StudyActive, not recruitingNCT03517137Phase 2Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung CancerTerminatedNCT03505710Phase 2Results posted
• Combination Chemotherapy and Inotuzumab Ozogamicin in Treating Patients With B Acute Lymphoblastic LeukemiaTerminatedNCT03488225Phase 2Results posted
• A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)CompletedNCT03474107Phase 3Results posted
• A Trial of Tisotumab Vedotin in Cervical CancerCompletedNCT03438396Phase 2Results posted
• Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell LymphomaCompletedNCT03409432Phase 2Results posted
• OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT03390296Phase 1/2Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)CompletedNCT03384940Phase 2Results posted
• Study of DS-8201a for Participants With Advanced Solid Malignant TumorsCompletedNCT03383692Phase 1Results posted
• Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid LeukemiaCompletedNCT03374332Phase 1/2Results posted
• DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) ProteinCompletedNCT03368196Phase 1Results posted
• Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval and Pharmacokinetics in HER2-Expressing Breast CancerCompletedNCT03366428Phase 1Results posted
• A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedNCT03337698Phase 1/2Results posted
• Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing TherapyActive, not recruitingNCT03334617Phase 2Results posted
• DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]CompletedNCT03329690Phase 2Results posted
• BV-CHEP Chemotherapy for Adult T-cell Leukemia or LymphomaCompletedNCT03264131Phase 2Results posted
• A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)TerminatedNCT03248492Phase 2Results posted
• Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.CompletedNCT03245736Phase 2Results posted
• Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin LymphomaActive, not recruitingNCT03233347Phase 2Results posted
• Brentuximab Vedotin for Systemic SclerosisCompletedNCT03222492Phase 1/2Results posted
• A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder CancerCompletedNCT03219333Phase 2Results posted
• A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,TerminatedNCT03138499Phase 3Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaActive, not recruitingNCT03113500Phase 2Results posted
• Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast CancerCompletedNCT03106077Phase 2Results posted
• Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic LeukemiaTerminatedNCT03094611Phase 2Results posted
• Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin LymphomaActive, not recruitingNCT03057795Phase 2Results posted
• A Study Of Pembrolizumab In Combination With Trastuzumab-DM1CompletedNCT03032107Phase 1Results posted
• A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid TumorsCompletedNCT02999672Phase 2Results posted
• Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell TumorsTerminatedNCT02988843Phase 2Results posted
• Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast CancerCompletedNCT02980341Phase 1/2Results posted
• A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin LymphomaActive, not recruitingNCT02979522Phase 1/2Results posted
• Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)CompletedNCT02939014Phase 2Results posted
• Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin LymphomaActive, not recruitingNCT02758717Phase 2Results posted
• Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02744612Phase 2Results posted
• Brentuximab Vedotin in Relapsed/Refractory Germ Cell TumorsTerminatedNCT02689219Phase 2Results posted
• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)TerminatedNCT02669264Phase 1Results posted
• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)CompletedNCT02669017Phase 1Results posted
• A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a TaxaneCompletedNCT02658734Phase 4Results posted
• Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast CancerTerminatedNCT02658084Phase 1/2Results posted
• A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube CancerCompletedNCT02631876Phase 3Results posted
• Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube CancerCompletedNCT02606305Phase 1/2Results posted
• A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02600897Phase 1/2Results posted
• Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell LymphomaTerminatedNCT02594163Phase 2Results posted
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)CompletedNCT02588651Phase 2Results posted
• An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin LymphomasCompletedNCT02581631Phase 1/2Results posted
• Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)CompletedNCT02574455Phase 3Results posted
• A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin LymphomaCompletedNCT02572167Phase 1/2Results posted
• Study of DS-8201a in Subjects With Advanced Solid Malignant TumorsCompletedNCT02564900Phase 1Results posted
• T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT02562378Phase 1Results posted
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02552121Phase 1/2Results posted
• Dose Ranging Study of Brentuximab Vedotin in Adults With LupusTerminatedNCT02533570Phase 2Results posted
• A Study of LY3076226 in Participants With Advanced or Metastatic CancerCompletedNCT02529553Phase 1Results posted
• Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin LymphomaCompletedNCT02505269Phase 2Results posted
• Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02429375Phase 1/2Results posted
• A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCLCompletedNCT02423291Phase 2Results posted
• Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive LymphomasCompletedNCT02388490Phase 2Results posted
• T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCAActive, not recruitingNCT02326974Phase 2Results posted
• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CMLCompletedNCT02311998Phase 1/2Results posted
• A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02289833Phase 2Results posted
• A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell LymphomaCompletedNCT02257567Phase 1/2Results posted
• Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT02227199Phase 1/2Results posted
• A Study Of PF-06647020 For Adult Patients With Advanced Solid TumorsCompletedNCT02222922Phase 1Results posted
• Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)TerminatedNCT02169505Phase 2Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin LymphomaActive, not recruitingNCT02166463Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast CancerTerminatedNCT02144012Phase 3Results posted
• A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCompletedNCT02131064Phase 3Results posted
• Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)TerminatedNCT02096042Phase 1/2Results posted
• Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelCompletedNCT02073487Phase 2Results posted
• Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916CompletedNCT02064387Phase 1Results posted
• Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid TumorsCompletedNCT02001623Phase 1/2Results posted
• Brentuximab Vedotin and Chemotherapy in CD30+ PMBL, Diffuse Large B-Cell, and Grey Zone Lymphoma PatientsCompletedNCT01994850Phase 1/2Results posted
• A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01990534Phase 4Results posted
• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell LymphomaCompletedNCT01979536Phase 2Results posted
• A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast CancerCompletedNCT01966471Phase 3Results posted
• A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell LymphomaCompletedNCT01950364Phase 1Results posted
• Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)TerminatedNCT01925612Phase 2Results posted
• S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute LeukemiaCompletedNCT01925131Phase 1Results posted
• Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin LymphomaActive, not recruitingNCT01920932Phase 2Results posted
• Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell LymphomaCompletedNCT01909934Phase 4Results posted
• Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin LymphomaCompletedNCT01874054Phase 1/2Results posted
• T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)CompletedNCT01853748Phase 2Results posted
• Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30TerminatedNCT01841021Not applicableResults posted
• Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell LeukemiaCompletedNCT01807598Phase 2Results posted
• Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
• Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01780662Phase 1/2Results posted
• ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell LymphomasCompletedNCT01777152Phase 3Results posted
• A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)CompletedNCT01772472Phase 3Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin LymphomaCompletedNCT01771107Phase 1/2Results posted
• A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)CompletedNCT01716806Phase 2Results posted
• A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin LymphomaCompletedNCT01712490Phase 3Results posted
• Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ LymphomaActive, not recruitingNCT01703949Phase 2Results posted
• A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based TreatmentCompletedNCT01702571Phase 3Results posted
• A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)TerminatedNCT01702558Phase 2Results posted
• Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia TreatmentCompletedNCT01698879Phase 2Results posted
• Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing ChemotherapyCompletedNCT01679119Phase 2Results posted
• CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid MalignanciesCompletedNCT01664910Phase 1/2Results posted
• Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)CompletedNCT01657331Phase 1/2Results posted
• A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric CancerTerminatedNCT01641939Phase 2/3Results posted
• Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerCompletedNCT01631552Phase 1/2Results posted

← Antibody-drug conjugates (ADCs) overview